Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Danish company Novo Nordisk's membership in a UK pharmaceutical industry body has been restored after a two-year suspension ...

Falling short of expectations, Novo Nordisk said its investigational fixed-dose combination of cagrilintide and semaglutide ...

Receiving an electronic reminder about influenza vaccination appeared to decrease COVID vaccination rates. Further study of ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from country's drug ...

Novo Nordisk’s (NVO) etavopivat was granted FDA orphan designation for treatment of thalassemias, according to a post on the agency’s ...

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

In this video, I will cover the recent updates regarding Novo Nordisk (NYSE: NVO). Watch the short video to learn more, ...